These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23782591)

  • 21. Evaluation of rivastigmine in Alzheimer's disease.
    Nguyen K; Hoffman H; Chakkamparambil B; Grossberg GT
    Neurodegener Dis Manag; 2021 Feb; 11(1):35-48. PubMed ID: 33198569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
    Froelich L; Gertz HJ; Heun R; Heuser I; Jendroska K; Kornhuber J; Kurz A; Mueller-Thomsen T; Ries F; Waechtler C; Metz M; Goebel C
    Dement Geriatr Cogn Disord; 2004; 18(1):37-43. PubMed ID: 15084792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
    Kurz A; Van Baelen B
    Dement Geriatr Cogn Disord; 2004; 18(2):217-26. PubMed ID: 15237280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer's disease patients: study protocol for a randomized controlled trial.
    Peng W; Zhou J; Xu M; Feng Q; Bin L; Liu Z
    Trials; 2017 Jul; 18(1):301. PubMed ID: 28673322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).
    Fereshtehnejad SM; Johnell K; Eriksdotter M
    Drugs Aging; 2014 Mar; 31(3):215-24. PubMed ID: 24497071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 29. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
    Seltzer B
    J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.
    Gareri P; Castagna A; Cotroneo AM; Putignano D; Conforti R; Santamaria F; Marino S; Putignano S
    J Alzheimers Dis; 2017; 56(2):557-565. PubMed ID: 28035929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
    Wattmo C; Paulsson E; Minthon L; Londos E
    Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
    Blesa R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.
    Gardette V; Lapeyre-Mestre M; Piau A; Gallini A; Cantet C; Montastruc JL; Vellas B; Andrieu S;
    CNS Drugs; 2014 Feb; 28(2):157-70. PubMed ID: 24408842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galantamine for Alzheimer's disease.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cholinesterase inhibitor therapy in long term care settings].
    Vantelon C; Gilbert S; Kerneis S; Wolmark Y; Legrain S; Kergoat MJ
    Rev Med Interne; 2006 Aug; 27(8):588-94. PubMed ID: 16806591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ABC of Alzheimer's disease: behavioral symptoms and their treatment.
    Grossberg GT
    Int Psychogeriatr; 2002; 14 Suppl 1():27-49. PubMed ID: 12636179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.